Stockscreener 앱 받기
1.70
15.00%
-0.30
시간 외 거래:
1.61
-0.09
-5.29%
Scisparc Ltd 주식(SPRC)의 최신 뉴스
No cash would flow to SciSparc (SPRC) under a proposed debt-for-shares conversion. - Stock Titan
Net loss narrows to $6.05M, but SciSparc (SPRC) raises substantial doubt about continuing operations. - Stock Titan
First human trial gets approval as Polyrizon (PLRZ) reports a wider six-month loss. - Stock Titan
SciSparc Announces Updates Regarding its Phase IIb Study in Tourette Syndrome - OTC Markets
SciSparc Awarded Three Patents For Its Novel Compounds and Methods - OTC Markets
Scisparc Ltd (SPRC) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
SciSparc’s NeuroThera Advances Enrollment in SCI-210 Autism Trial - TipRanks
Tourette drug cut tics 21% in study as SciSparc (SPRC) advances trials - Stock Titan
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - The Manila Times
A Tourette drug candidate achieved an average 21% tic reduction in an earlier study - Stock Titan
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - marketscreener.com
SciSparc Ltd. SEC Filing (Sep 1, 2026) - Stock Titan
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial - The Manila Times
26 children have joined SciSparc’s two-compound autism treatment trial - Stock Titan
Neurothera Labs Inc. Announces Share Consolidation - TradingView
Neurothera Labs Inc. Announces Share Consolidation - FinancialContent
Neurothera Labs Inc. Announces Share Consolidation - TheNewswire
SciSparc appoints AI professor to advisory board By Investing.com - Investing.com South Africa
SciSparc appoints AI professor to advisory board - Investing.com
SciSparc appoints AI professor to advisory board By Investing.com - Investing.com Canada
SciSparc appoints AI professor to advisory board By Investing.com - Investing.com India
Scisparc Ltd. Announces Appointment of Prof. Carmel Domshlak to Scientific Advisory Board for Ai and Cybersecurity, Effective September 1, 2026 - marketscreener.com
SciSparc (SPRC) Levels: Finishes 1.50% Up at $6.78 in the Current Update; Market Levels: Support at $6.44 and Resistance at $7.12 Frame the Range for the Current SessionIV Crush Alert - vinanet.vn
SciSparc subsidiary publishes MDMA combination patent application By Investing.com - Investing.com Canada
SciSparc (SPRC) adds MDMA-PEA PTSD patent with Clearmind - Stock Titan
SciSparc subsidiary publishes MDMA combination patent application By Investing.com - Investing.com India
SciSparc subsidiary publishes MDMA combination patent application By Investing.com - Investing.com UK
SciSparc (SPRC) Levels: Finishes 1.50% Up at $6.78 in the Current Update; Market Levels: Support at $6.44 and Resistance at $7.12 Frame the Range for the Current SessionCommon Gap - careplusvn.com
SciSparc (SPRC) Levels: Finishes 1.50% Up at $6.78 in the Current Update; Market Levels: Support at $6.44 and Resistance at $7.12 Frame the Range for the Current SessionSpring Pattern - dars.gov.et
FDA Guidance Includes MDMA as a Psychedelic Drug; SciSparc Patent Application Published - Stock Titan
SciSparc Ltd.Ordinary Shares (NQ: SPRC - The Chronicle-Journal
SciSparc | F-3/A: Registration statement for specified transactions by certain foreign private issuers (Amendment) - Moomoo
Scisparc posts audited 2025 net loss of USD 12.56 million - Bitget
SciSparc : Amendment to Annual Report by Foreign Issuer (Form 20-F/A) - marketscreener.com
SciSparc Boosts NeuroThera Stake in C$5.4 Million Financing - TipRanks
SciSparc (NASDAQ: SPRC) backs NeuroThera in C$5.4M raise - Stock Titan
SciSparc funds NeuroThera Labs spinoff with CAD 5.4m financing round - AllSci
SciSparc invests C$2.7M in subsidiary NeuroThera financing By Investing.com - Investing.com
SciSparc invests C$2.7M in subsidiary NeuroThera financing By Investing.com - Investing.com Canada
SciSparc Invests C$2.7 Million in NeuroThera Financing, Increases Stake to Approximately 44.6% - Moomoo
SciSparc Invests C$2.7 Million in NeuroThera Financing, Increases Stake to Approximately 44.6% - Quiver Quantitative
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 - GlobeNewswire
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million - Yahoo Finance
SciSparc Invests C$2.7 Million in NeuroThera Financing, Increases Stake to Approximately 44.6% - Quiver Quantitative
SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million - The Manila Times
Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement - TheNewswire
Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement - TradingView
SciSparc (SPRC) Gains 1.59% as Shares Hold Firm Above $6 Support ZonePut Call Ratio - vinanet.vn
SciSparc (SPRC) Gains 1.59% as Shares Hold Firm Above $6 Support ZoneRevenue Growth Stocks - dars.gov.et
4.22%
자본화:
|
볼륨(24시간):